Fintepla 2.2 mg/ml
Fintepla 2.2 mg/ml is a medicine authorised by Swissmedic under authorisation number 69371. The authorisation holder is UCB-Pharma SA. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 13 February 2025 and the authorisation is limited until 12 February 2030. ATC code N03AX26 places the medicine in the group Antiepileptics.
| Authorisation number | 69371 |
|---|---|
| Name | Fintepla 2.2 mg/ml |
| Full name | Fintepla 2.2 mg/ml, solution buvable |
| Authorisation holder | UCB-Pharma SA |
| Medicinal product code | Synthetic medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | N03AX26 |
| First authorisation | 13 February 2025 |
| Authorisation validity | 12 February 2030 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Fintepla 2.2 mg/ml, solution buvable | A | 13 February 2025 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 120 ml | Flasche(n) | N03AX26 | 01.07.1. | A |
| 2 | 360 ml | Flasche(n) | N03AX26 | 01.07.1. | A |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Fintepla 2.2 mg/ml authorised in Switzerland?
Yes. Fintepla 2.2 mg/ml is authorised by Swissmedic under authorisation number 69371, data as of 01 September 2026. The authorisation is limited until 12 February 2030.
Which dispensing category does Fintepla 2.2 mg/ml have?
Fintepla 2.2 mg/ml is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Fintepla 2.2 mg/ml?
The authorisation holder is UCB-Pharma SA. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.